AICAR analysis

The AICAR Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of AICAR in finished lyophilised vials and raw active pharmaceutical ingredient (API) powders.

For finished vials, results are reported in milligrams per vial. Raw API powders can be evaluated using an alternative result format based on purity in % (m/m). AICAR is not a peptide, and peptide purity is therefore not determined as part of this analysis.

About AICAR

AICAR is a small-molecule research compound widely used in studies of cellular energy metabolism and AMP-activated protein kinase (AMPK) signalling. After cellular uptake, AICAR riboside can be phosphorylated to ZMP, an AMP analogue that can activate AMPK.

AICAR has been investigated extensively in preclinical research examining metabolic regulation, glucose and lipid metabolism, and cellular responses to changes in energy availability. Its effects are not exclusively mediated through AMPK, and additional AMPK-independent mechanisms have also been described.

Key Features

• Targeted identification and quantification of AICAR
• Suitable for finished lyophilised vials and raw API powders
• Analysis by HPLC
• Results for finished vials reported in mg per vial
• Alternative purity reporting in % (m/m)
• Minimum sample amount of one whole unopened vial with lyophilisate
• Minimum sample amount of 30 mg for raw API powder
• Average turnaround time of 7 business days

Analysis Parameters

• Target compound: AICAR
• Testing method: HPLC
• Result format for finished vial: mg per vial
• Alternative result format: Purity in % (m/m)
• Minimum sample amount for finished vial: One whole unopened vial with lyophilisate
• Minimum sample amount for raw API powder: 30 mg in a sealed glass vial to prevent the sample from absorbing moisture
• Average turnaround time: 7 business days

Important Notice

• AICAR is not a peptide. Peptide purity is therefore not measured as part of this analysis.
• For finished products, one whole unopened vial containing lyophilisate is required.
• Raw API powder should be supplied as at least 30 mg in a sealed glass vial to minimise moisture absorption.

Optional Additional Analyses

The following optional laboratory services are available:

• Complete Raw Analytical Data
• Fentanyl Screening
• Alternative Result Format: Purity in % (m/m) – only for raw API powders
• Batch Variance Testing
• pH Measurement
• Endotoxin Analysis
• CHNS Mass Report
• LCMS Screening For Peptide Contamination
• Heavy Metals Analysis (As, Cd, Pb, Hg)
• Sterility Testing (TAMC and TYMC)
• Additional Laboratory Report